ArticlePLoS neglected tropical diseases2016
Identifying Leprosy and Those at Risk of Developing Leprosy by Detection of Antibodies against LID-1 and LID-NDO.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The Predictive Role of Biomarkers for Leprosy Prophylaxis in Contacts of Patients Who Are Indices of the Disease: A Systematic Review of the Literature.Mediators of inflammation · 2026Pooled it
- Mycobacterium leprae infection, Hansen's disease, and helminth infections: A cross-sectional study in southeastern Brazil.PLoS neglected tropical diseases · 2026Article
- Biosensor-Based Platforms for the Detection and Screening ofACS infectious diseases · 2026Review
- High seropositivity against NDO-LID in a group of household contacts of leprosy patients. Are we close to leprosy elimination in Colombia?Pathogens and global health · 2023Observational
- Arginase 1 is a marker of protection against illness in contacts of leprosy patients.Scientific reports · 2022Article
- Algorithm Design for a Cytokine Release Assay of Antigen-Specific In Vitro Stimuli of Circulating Leukocytes to Classify Leprosy Patients and Household Contacts.Open forum infectious diseases · 2022Article
- Modulation of the Response toFrontiers in microbiology · 2022Review
- Detection of Mycobacterium leprae DNA in clinical and environmental samples using serological analysis and PCR.Molecular biology reports · 2021Article
- Latent leprosy infection identified by dual RLEP and anti-PGL-I positivity: Implications for new control strategies.PloS one · 2021Article
- Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2020Article
- Prospects for new leprosy diagnostic tools, a narrative review considering ELISA and PCR assays.Revista da Sociedade Brasileira de Medicina Tropical · 2020Review
- Social and environmental conditions related to Mycobacterium leprae infection in children and adolescents from three leprosy endemic regions of Colombia.BMC infectious diseases · 2019Article
- A novel integrated molecular and serological analysis method to predict new cases of leprosy amongst household contacts.PLoS neglected tropical diseases · 2019Article
- Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil.BMC infectious diseases · 2019Article
- Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.PLoS neglected tropical diseases · 2019Article
- Leprosy: prevalence and factors associated with seropositivity for anti-NDO-LID antibodies in children under 15 years of age.Anais brasileiros de dermatologia · 2019Article
- Evaluation of antigen-specific immune responses for leprosy diagnosis in a hyperendemic area in China.PLoS neglected tropical diseases · 2018Article
- Article
- Accuracy of Enzyme-Linked Immunosorbent Assays (ELISAs) in Detecting Antibodies againstThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy is caused by Mycobacterium leprae infection and remains a major public health problem in many areas of the world. Challenges to its timely diagnosis result in delay in treatment, which is usually associated with severe disability. Although phenolic glycolipid (PGL)-I has been reported as auxiliary diagnostic tool, currently there is no serological assay routinely used in leprosy diagnosis. The aim of this study was to evaluate the effectiveness of two related reagents, LID-1 and LID-NDO, for the detection of M. leprae infection. Sera from 98 leprosy patients, 365 household contacts (HHC) and 98 endemic controls from Rio Grande do Norte, Brazil, were evaluated. A subgroup of the HHC living in a hyperendemic area was followed for 7-10 years. Antigen-specific antibody responses were highest in multibacillary (MB) at the lepromatous pole (LL/BL) and lowest in paucibacillary (PB) at the tuberculoid pole (TT/BT). A positive correlation for both anti-LID-1 and anti-LID-NDO antibodies was found with bacterial burden (LID-1, r = 0.84, p<0.001; LID-NDO, r = 0.82, p<0.001), with higher sensitivity than bacilloscopy. According to Receiver Operating Curve, LID-1 and LID-NDO performed similarly. The sensitivity for MB cases was 89% for LID-1 and 95% for LID-NDO; the specificity was 96% for LID-1 and 88% for LID-NDO. Of the 332 HHC that were followed, 12 (3.6%) were diagnosed with leprosy in a median time of 31 (3-79) months after recruitment. A linear generalized model using LID-1 or LID-NDO as a predictor estimated that 8.3% and 10.4% of the HHC would become a leprosy case, respectively. Together, our findings support a role for the LID-1 and LID-NDO antigens in diagnosing MB leprosy and identifying people at greater risk of developing clinical disease. These assays have the potential to improve the diagnostic capacity at local health centers and aid development of strategies for the eventual control and elimination of leprosy from endemic areas.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.